Mark Hickman Selected Research

Malaria

1/2018	The use of Fionet technology for external quality control of malaria rapid diagnostic tests and monitoring health workers' performance in rural military health facilities in Tanzania.
1/2017	Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites.
12/2016	Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
2/2016	Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes.
1/2016	Field evaluation of diagnostic performance of malaria rapid diagnostic tests in western Kenya.
1/2016	Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
4/2014	Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
1/2014	Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice.
1/2013	Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity.
3/2012	Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Hickman Research Topics

Disease

11	Malaria 01/2018 - 01/2011
6	Infections 01/2023 - 04/2014
2	Cysts 01/2024 - 01/2016
1	Anthrax 01/2023
1	Body Weight (Weight, Body) 01/2021
1	Melioidosis 01/2021
1	Pain (Aches) 02/2019
1	Leishmaniasis 03/2014
1	Cutaneous Leishmaniasis 03/2014
1	Glucosephosphate Dehydrogenase Deficiency 06/2013
1	Hemolytic Anemia 06/2013
1	Inflammation (Inflammations) 01/2011
1	Human Influenza (Influenza) 05/2003

Drug/Important Bio-Agent (IBA)

8	Antimalarials (Antimalarial Agents)IBA 01/2017 - 03/2012
4	Primaquine FDA Link 12/2016 - 06/2013
3	DecoquinateIBA 01/2017 - 01/2013
2	delafloxacinIBA 01/2023 - 01/2021
2	tafenoquineIBA 12/2016 - 04/2014
1	gamma-Aminobutyric Acid (GABA)IBA 01/2024
1	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2023
1	Ceftazidime (Fortum)FDA LinkGeneric 01/2021
1	LuciferasesIBA 02/2016
1	Cytochromes b (Cytochrome b)IBA 01/2016
1	Fluoxetine (Prozac)FDA LinkGeneric 01/2016
1	Electron Transport Complex III (Coenzyme Q-Cytochrome-c Reductase)IBA 01/2016
1	GoldIBA 03/2014
1	Ketotifen (Ketotifene)FDA Link 03/2012
1	ArtemisininsIBA 01/2011
1	ArtesunateIBA 01/2011
1	artemisinin (artemisinine)IBA 01/2011
1	Proteins (Proteins, Gene)FDA Link 05/2003

Therapy/Procedure

4	Therapeutics 01/2018 - 01/2011
1	Euthanasia (Mercy Killing) 02/2019
1	Injections 01/2011
1	Intramuscular Injections 01/2011